One hundred consecutive patients hospitalized in the coronary care unit for unstable angina, excluding patients with Prinzmetal's variant angina, were randomized within 24 hours of admission to treatment with diltiazem (50 patients) or propranolol (50 patients). Also excluded were patients with previous coronary artery bypass surgery and those receiving a beta-receptor blocking agent at the time of hospital admission. Left ventricular function and the extent of coronary artery disease were similar in the two groups.
During the hospital stay, the number of chest pain episodes decreased from a mean (± SD) of 0.75 ± 0.1 per patient per day to 0.26 ± 0.07 (p < 0.05) with diltiazem and 0.29 ± 0.1 (p < 0.05) with propranolol therapy. The circadian distribution of chest pain episodes was affected similarly. After 1 month, 14 of the patients treated with diltiazem were symptom-free comRecognition of the role of coronary artery vasomotion in ischemic heart disease has aided understanding of many of the clinical aspects of angina (I). Thus, whereas a fixed atherosclerotic obstruction appears to be the usual cause of angina occurring during exercise, spasm or abnormal coronary artery tone is believed to play a major role in rest angina and, consequently, in unstable angina (1,2). Calcium channel antagonists prevent coronary artery spasm, but betareceptor blocking drugs may aggravate it (3) . For these reasons, many studies (4-11) have been performed in recent years using calcium channel antagonists in patients with unstable angina. Although favorable clinical results were generally reported, most studies dealt with a small number of patients often treated with a combination of drugs, and patients with ST segment depression and ST segment ele-pared with 13 treated with propranolol. At a mean follow-up time of 5.1 months (range 1 to 15), death had occurred in two patients in each group and myocardial infarction in fivediltiazem-and four propranolol-treated patients (difference not significant). Coronary artery bypass surgery had been performed in 21 dihiazem-and 19 propranolol-treated patients (difference not significant). Only 15 patients were symptom-free, 9 treated with diltiazem and 6 with propranolol.
This similar result observed with the two forms of treatment suggests that coronary artery spasm may not be the main factor involved in unstable angina when Prinzmetal's variant angina is excluded. It also suggests that diltiazem can be used as an alternative to the usual treatment with beta-receptor blocking drugs.
(J Am Coil CardioI1985; 5:717-22) vation during episodes of chest pain were included without distinction.
The pathophysiology of these two electrocardiographic manifestations of myocardial ischemia may, however, differ and various mechanisms other than spasm may account for unstable angina, such as progression in coronary artery disease (12) , enhanced platelet reactivity (13, 14) and prostaglandins (15) . The purpose of our study was to compare the clinical efficacy of a calcium channel antagonist (diltiazem) and of a beta-receptor blocking drug (propranolol) in patients hospitalized with unstable angina, excluding patients with the clinical syndrome of Prinzmetal's variant angina.
Methods
Study patients. All patients admitted to the coronary care unit with the clinical diagnosis of unstable angina during the study period were considered for the study. Unstable angina was diagnosed whenever one of the following clinical conditions was present (16): 1) crescendo angina defined by the presence of chest pain with a recent increase in fre- Table 1 . Patient Selection and Exclusion Factors quency, intensity and duration; 2) acute coronary insufficiency, that is, prolonged ischemic chest pain poorly relieved by nitroglycerin and without electrocardiographic or serum enzyme evidence of myocardial infarction; and 3) spontaneous angina occurring 3 to 30 days after an acute myocardial infarction. Inclusion in the study required documentation of transient ST segment or T wave changes during an episode of chest pain . Prinzmetal's variant angina was diagnosed when the electrocardiographic change consisted of ST segment elevation; patients with this finding were excluded from the study . The diagnosis of unstable angina was confirmed independently by two cardiologists.
Ofa total of543 consecutive patients with this diagnosis. 100 signed the informed consent form and entered the trial. The 443 other patients were excluded for the various reasons defined in the original protocol ( Table I ). The most frequent reasons for exclusion were age older than 65 years (60 patients), previous coronary artery bypass surgery (74 patients) , documented variant angina (76 patients) and treatment with a beta-receptor blocking drug at the time of hospital admission (IOI patients). This last exclusion criterion was retained to avoid a possible rebound clinical effect when stopping the medication . Other exclusion factors were participation in another clinical trial , contraindication to one of the study medications, coronary artery bypass surgery already planned, patient or physician refusal and a followup not possible for psychologic or physical reasons.
Patient management. All patients were hospitalized in the coronary care unit. Bed rest, a mild sedative and isosorbide dinitrate, 120 mg daily or as tolerated, were prescribed . Aspirin was riot administered because no evidence of a beneficial effect existed at the time of the study. An electrocardiographic lead was continuously monitored. Serial enzyme determination was performed to rule out myocardial infarction. A 12 lead electrocardiographic tracing was rapidly obtained on a three channel recorder whenever the patient experienced an episode of chest pain, before the Treatment protocol. After the patient was judged to be eligible for the study and written informed consent was obtained, the patients were randomized to one of the two study drugs. Randomization was done by a computer-generated hazard selection of drugs and equilibrated into blocks of nine cases. The study drug was administered in singleblind fashion within 12 to 24 hours after admission and consisted of either 60 mg of diltiazem or 40 mg of propranolol. If this first dose was well tolerated, the dosage of diltiazem was increased to 120 mg, three times daily, and of propranolol to 80 mg, three times daily. The protocol was then adjusted to the current management of unstable angina patients. Blood pressure and heart rate were recorded . If the patient became free of pain, he or she was progressively mobilized and coronary arteriography performed after 3 to 6 days. If the clinical condition remained unstable despite the high doses of the medication, the period of bed rest was prolonged and an intravenous infusion of nitroglycerin was started at a rate adjusted to the clinical and hemodynamic response. Early coronary angiography was considered if chest pain persisted despite this treatment. At this stage, the option of a therapeutic trial with the other study drug was given.
Coronary arteriography was performed in 93 patients; in 7, it was not done because of the early occurrence of myocardial infarction or death . A stenosis reducing the luminal diameter by 70% or more was considered significant. A left ventriculogram was obtained in the 30°right anterior oblique projection in 76 patients; it was not obtained in 17 patients judged at higher risk by the cardiologist performing the catheterization.
Persistent chest pain during hospitalization was an indication for coronary artery bypass surgery whenever possible . The reason for bypass surgery in these patients was classified as refractory angina . Surgery was also performed on asymptomatic patients for elective reasons on the basis of the severity of the coronary obstructive lesions . The medication was withheld on the day of surgery and resumed 5 days after and continued during the follow-up period .
Follow-up. All patients were discharged taking the medication to which they originally had been allocated, except for the four patients who crossed over to treatment with the other study drug . The study drug was stopped in three patients and the dose reduced in four others because of suspected side effects; four of these patients were receiving diltiazem and three were receiving propranolol. Follow-up was obtained in a special unstable angina clinic I month after randomization and every 3 months thereafter. A com- Statistical analysis. The clinical characteristics of the patients at admission were compared by an unpaired Student's t test for continuous variables and by a chi-square test for discrete variables. An analysis of variance corrected for repeated measures over time was used to compare the hemodynamic response with both drugs during the hospital stay. The clinical outcome with the two forms of treatments was analyzed by the log-rank test.
Results
Clinical and angiographic characteristics. Fifty patients were randomized to diltiazem and 50 to propranolol. Age, sex, family history of coronary artery disease, incidence of previous myocardial infarction and diabetes, smoking habits and cholesterol blood levels were similar in the two treatment groups ( Table 2 ). History of past hypertension was more frequent in the diltiazem group (I8 versus 9 patients, p < 0.05). Although the same number of patients had an abnormal basal electrocardiogram, the two groups differed with regard to the clinical manifestation of unstable angina. Crescendo angina was more frequent in the pro- patients with spontaneous angina after myocardial infarction was the same in both groups.
Coronary angiography showed absence of significant (70% or greater) vessel stenosis in 9 of 93 patients; 36 patients had one vessel disease, 34 two vessel disease and 14 three vessel disease. An abnormal ventriculogram was found in 34 of the 76 patients who had the test. The extent of coronary artery disease and left ventricular impairment were equally distributed among the two treatment groups (Table 2) .
Hemodynamic response to medication. Blood pressure and heart rate were recorded four times daily during hospitalization. Figure I displays the daily average of the four recordings and also the rate-pressure product. At baseline level, systolic blood pressure, heart rate and rate-pressure product were very similar in the two treatment groups. After treatment, all three hemodynamic variables became significantly lower. The decrease was slightly greater with propranolol, but the difference was not statistically significant compared with diltiazem.
First month follow-up. Before treatment, the mean number (± standard deviation) of episodes of chest pain per day was 0.75 ± 0.1 per patient. With propranolol, it decreased to 0.26 ± 0.07 and with diltiazem to 0.29 ± Figure 1 . Hemodynamic responses to treatment. The four daily recordings of heart rate (HR), systolic blood pressure (SYST BP) and rate-pressure product (HR x SYST BP) were averaged to give a value before treatment (day 0) and daily thereafter for the first week of treatment. Significant reduction in the three variables is observed with each drug compared with baseline level, but.the difference between the two treatments is not significant (NS). The circadian distribution of episodes of chest pain was also affected similarly (Fig. 2) . The incidence was minimal at night and increased during the day to peak in the evening . This curve was flattened by the two medications. Figures 3 and 4 summari ze the clinical evolution during hospitali zation and during the fir st month follow-up for the 100 patients . Death occurred in two patients in each treatment group; three patients taking diltiazem had a myocardial infarction compared with two patients taking propranolol. Coronary artery bypass surgery was performed in 15 patients receiv ing diltiazem and 16 receiving propranolol; the indication was persistent angina for , respectively, 6 and 4 patients and severity of the coronary artery lesion for 9 and 12 patients (difference not significant). Thirty-nine patients taking diltiazem and 40 taking propranolol became anginafree during the hospital stay . Angina recurred in the early post-hospital phase in 16 and 17 patient s, respectively. One of the seven patients with persistent angina while taking diltiazern was treated with propranolol and became symptom-free . Three patients taking propranolol were crossed over to diltiazem; two had a favorable result , but the other patient died. Overall , after I month , 27 of the medically treated patients were symptom-free (14 from the diltiazem group and 13 from the propranolol group) .
Long-term follow-up. The clinical evolution remained similar during the long-term foIlow-up period, which extended to a mean of 5.1 months (range I to IS) (Fig. 5) . Myocardial infarction occurred in an additional four pa- of the 50 patients randomized to diltia zem therapy and of the 50 patients randomized to propranolol therapy . The clinical evolution was very similar in the two groups. Abbreviation s as in Figure 3 . tients, two in the diltiazem group and two in the propranolol group . Nonscheduled coronary artery bypass surgery motivated by recurrence of angina was performed in six patient s taking diltiazem and three patients taking propranolol. Angina disappeared in three patients receiving diltiazem and reappeared in two patients receiving propranolol. Without coronary artery bypass surgery , 15 of the 100 patients originally enrolled were symptom-free after a mean of 5.1 months, 9 in the diltiazem group and 6 in the propranolol group.
Discussion
In this clinical trial using at random a calcium channel antagonist or a beta-receptor blocking drug for the management of unstable angina, very similar results were found with the two forms of treatment. The reduction in the number of chest pain episodes, the occurrence of major events (death and myocardial infarction) and the need for coronary artery bypass surgery during hospitalization and follow-up were the same with diltiazem and propranolol treatment.
Previous studies on calcium antagonists in unstable angina. Most previous studie s have suggested that a calcium channel antagoni st could be a better choice for treating unstable angina. However, significantly different protocol s were used . All these studies (4-11) enrolled patients with ST segment elevation as well as patients with ST segment depression during the episodes of chest pain , the proportion of patients with ST segment elevation varying between 27 and 67%. In many of these studie s (4, 5, 8) , the beneficial effect of the calcium channel antagonist was limited to the subset of patients with ST segment elevation . In the study of Gerstenblith et al. (8) , 138 patients treated with propranolol and nitrates received at random placebo or nifedipine treatment. After 4 months of follow-up, significantly fewer treatment failures defined by death, myocardial infarction or the need for coronary artery surgery had occurred in the nifedipine group (30 of 68 patients taking nifedipine compared with 43 of 70 patients taking placebo, p < 0 .03).
The difference favoring nifedipine was found exclusively in patients with ST segment elevation; in patients with ST segment depression, failure occurred in 21 of the 42 patients receiving nifedipine and in 25 of the 43 receiving placebo .
Another important protocol difference is that the majority of the studie s (6,7,9-11) evaluated a combination of treatment with a nitrate , a beta-receptor blocking agent and a calcium channel antagonist versus a nitrate and a beta-receptor blocking drug. In many studies (5, 6, 10) , a calcium channel antagonist was added to the usual treatment in those patients unresponsive to the usual treatment during the first few hours after admission. In the study by Gerstenblith et al. (8) , all patients received propranolol. In the study by Muller et al. (11), approximately half received propranolol while the other half received either propranolol or nifedipine . In this last study, nifedipine was found to be equivalent to conventional therapy for controlling chest pain and preventing myocardial infarction and death.
Study design. The patients included in our study may not be representative of the entire cohort of patients with the clinical syndrome of unstable angina . A selection was made by excluding patients demonstrating ST segment elevation during the episode s of chest pain , representing 14% of our consecutive series of patients hospitalized for unstable angina . Transient ST segment elevation during chest pain is the diagnostic criterion for Prinzmetal's variant angina ( 17) . Coronary artery vasomotion or spasm has been documented to be the causative factor for this syndrome (18, 19) , whereas the exact mechanism for unstable angina has not yet been elucidated (12) (13) (14) (15) . In addition, only one active drug was given per patient to avoid a possible confounding effect on the results of a mixed treatment with beneficial effect of a calcium channel antagonist for coronary artery spasm (20,2 1) and a deleterious effect of a beta-receptor blocking drug (3,20 ,22) . In our series , exclusion of patient s already taking beta-receptor blocking drugs could have reduced the number of patient s with three vessel disease, although the distribution of the severity of the disease represents the spectrum of coronary artery disease and is comparable with that of other series (12, 23) .
The design of our study , however, does not eliminate the possibility of added benefit in some patients of the combined treatment , nor does it document that treatment with an active drug is superior to treatment with placebo since the latter was not used. However, use of a beta-receptor blocking drug with nitrates is now the standard therapy for unstable angina and our result s suggest that diltiazem may be as effective as propranolol. Use of a more aggressive nitrate regimen titrated to the individual patient according to tolerance or hemodynamic response could have significantly altered our results, particularly of chest pain control (24) .
Study results. The results do not allow extrapolation on the mechanism of action of diltiazem. Heart rate, blood pressure and the rate-pressure product (the external indexes of myocardial oxygen consumption) were slightly less reduced than with propranolol , but the differences were not significant. No attempt was made to coordinate the recordings of heart rate and blood pressure with the ingestion of the drugs; they simpl y repre sent the average of the daily routine recordings. The fact that both a calcium channel antagonist and a beta-receptor blocking drug had similar clinical efficacy may suggest that coronary artery spasm is not the main factor involved in unstable angina when patients with ST segment elevation are excluded. The results . of the Veterans Admini stration Cooperative Study (14) showing a protective effect of aspirin against acute myocardial infarction and death in patients with unstable angina are consistent with this observation .
Although the patients were assigned to medication by randomization, differences in some baseline characteristics were observed. Patients with a previous history of hypertension were more numerous in the diltiazem group, although blood pressure and heart rate were very similar in patients in both groups at entry. A second difference between groups existed in the distribution of the type of angina. More patients in the propranolol group had a crescendo type of angina and more patients in the diltiazem group had acute coronary insufficiency. Responses to treatment might have been influenced by these differences since they may reflect different pathophysiologic mechanisms. However, previous myocardial infarction, the extent of coronary artery disease and left ventricular function were similar in the two groups, suggesting the absence of an important imbalance between groups. Although the number of patients was relatively large, a type II error cannot be ruled out considering that the most serious events (death and myocardial infarction) were relatively infrequent; potentially important differences could thus have been missed. However, the fact that no favorable trend with one form of treatment compared with the other was observed suggests that diltiazem may represent a valuable alternative to beta-receptor blocking agents in the treatment of unstable angina. This could be particularly important if a contraindication to beta-receptor blocking drugs exists or if vasospastic disease is suspected.
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